Prokidney (PROK) Income from Continuing Operations (2021 - 2026)
Prokidney (PROK) reported Income from Continuing Operations of 42621000.0 for Q1 2026, down 12.3% year-over-year from 48599951.69 in Q1 2025, and down 4.33% quarter-over-quarter from 40852000.0 in Q4 2025.
Prokidney (PROK) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Prokidney (PROK) has 6 years of Income from Continuing Operations data on file, last reported at 42621000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 42621000.0, down 12.3% year-over-year; the trailing twelve-month figure through Mar 2026 was 156281000.0 (up 5.83% YoY), and the FY2025 annual result was 151612000.0, up 7.18% from the prior year.
- Income from Continuing Operations fell to 42621000.0 in Q1 2026 per PROK's latest filing, from 40852000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 21724000.0 in Q4 2023 and troughed at 67486000.0 in Q1 2022.
- A 5-year average of 37714705.88 and a median of 36965000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations tumbled 1302215.71% in 2022, then soared 45.31% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 24573000.0 in 2022, then gained by 11.59% to 21724000.0 in 2023, then sank by 123.18% to 48483000.0 in 2024, then rose by 15.74% to 40852000.0 in 2025, then declined by 4.33% to 42621000.0 in 2026.
- Business Quant data shows PROK's Income from Continuing Operations at 42621000.0 in Q1 2026, 40852000.0 in Q4 2025, and 35843000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Prokidney | 259.01 Mn | 1.55 Bn | - | -42.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.62 Mn |
| Dec 31, 2025 | -40.85 Mn |
| Sep 30, 2025 | -35.84 Mn |
| Jun 30, 2025 | -36.97 Mn |
| Mar 31, 2025 | -37.95 Mn |
| Dec 31, 2024 | -48.48 Mn |
| Sep 30, 2024 | -41.05 Mn |
| Jun 30, 2024 | -38.47 Mn |
| Mar 31, 2024 | -35.33 Mn |
| Dec 31, 2023 | -21.72 Mn |
| Sep 30, 2023 | -41.99 Mn |
| Jun 30, 2023 | -34.82 Mn |
| Mar 31, 2023 | -36.91 Mn |
| Dec 31, 2022 | -24.57 Mn |
| Sep 30, 2022 | -33.95 Mn |
| Jun 30, 2022 | -22.13 Mn |
| Mar 31, 2022 | -67.49 Mn |
| Dec 31, 2021 | -13.82 Mn |
| Sep 30, 2021 | -17.02 Mn |
| Jun 30, 2021 | -5,325.00 |